ANNX
Price
$2.32
Change
-$0.02 (-0.85%)
Updated
Jul 18 closing price
Capitalization
254.54M
28 days until earnings call
ERAS
Price
$1.50
Change
+$0.06 (+4.17%)
Updated
Jul 18 closing price
Capitalization
424.93M
17 days until earnings call
Interact to see
Advertisement

ANNX vs ERAS

Header iconANNX vs ERAS Comparison
Open Charts ANNX vs ERASBanner chart's image
Annexon
Price$2.32
Change-$0.02 (-0.85%)
Volume$1.38M
Capitalization254.54M
Erasca
Price$1.50
Change+$0.06 (+4.17%)
Volume$701.3K
Capitalization424.93M
ANNX vs ERAS Comparison Chart in %
Loading...
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANNX vs. ERAS commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANNX is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (ANNX: $2.31 vs. ERAS: $1.50)
Brand notoriety: ANNX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANNX: 85% vs. ERAS: 55%
Market capitalization -- ANNX: $254.54M vs. ERAS: $424.93M
ANNX [@Biotechnology] is valued at $254.54M. ERAS’s [@Biotechnology] market capitalization is $424.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANNX’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ANNX’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ANNX and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANNX’s TA Score shows that 2 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • ANNX’s TA Score: 2 bullish, 6 bearish.
  • ERAS’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than ANNX.

Price Growth

ANNX (@Biotechnology) experienced а -10.47% price change this week, while ERAS (@Biotechnology) price change was +3.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

ANNX is expected to report earnings on Aug 18, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($425M) has a higher market cap than ANNX($255M). ERAS YTD gains are higher at: -40.239 vs. ANNX (-54.971). ERAS has higher annual earnings (EBITDA): -150.24M vs. ANNX (-180.76M). ERAS has more cash in the bank: 305M vs. ANNX (264M). ANNX has less debt than ERAS: ANNX (28.3M) vs ERAS (50.8M). ANNX (0) and ERAS (0) have equivalent revenues.
ANNXERASANNX / ERAS
Capitalization255M425M60%
EBITDA-180.76M-150.24M120%
Gain YTD-54.971-40.239137%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M305M87%
Total Debt28.3M50.8M56%
TECHNICAL ANALYSIS
Technical Analysis
ANNXERAS
RSI
ODDS (%)
Bearish Trend 4 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NRBT0.03N/A
+9.88%
Novus Robotics, Inc.
NUVSF10.220.15
+1.49%
NuVista Energy Ltd.
EVSYX26.100.04
+0.15%
Allspring Disciplined US Core Admin
AZNCX9.730.01
+0.10%
Virtus Income & Growth C
GMGMF0.57-0.02
-2.87%
Graphene Manufacturing Group Ltd.

ANNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with OCUL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANNX
1D Price
Change %
ANNX100%
-1.28%
OCUL - ANNX
47%
Loosely correlated
-0.44%
IDYA - ANNX
47%
Loosely correlated
-2.26%
ZYME - ANNX
46%
Loosely correlated
-1.59%
ERAS - ANNX
46%
Loosely correlated
+0.67%
TRML - ANNX
45%
Loosely correlated
-0.65%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.67%
RVMD - ERAS
54%
Loosely correlated
-1.92%
XNCR - ERAS
54%
Loosely correlated
-1.10%
OCUL - ERAS
53%
Loosely correlated
-0.44%
BEAM - ERAS
53%
Loosely correlated
+1.47%
ACLX - ERAS
52%
Loosely correlated
-4.74%
More